{"id":62718,"date":"2026-04-09T20:05:59","date_gmt":"2026-04-09T12:05:59","guid":{"rendered":"https:\/\/flcube.com\/?p=62718"},"modified":"2026-04-09T20:06:01","modified_gmt":"2026-04-09T12:06:01","slug":"unixell-biotechnology-secures-nmpa-ind-approval-for-ux-gip001-worlds-first-ipsc-derived-cell-therapy-for-drug-resistant-epilepsy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62718","title":{"rendered":"UniXell Biotechnology Secures NMPA IND Approval for UX-GIP001, World\u2019s First iPSC-Derived Cell Therapy for Drug-Resistant Epilepsy"},"content":{"rendered":"\n<p><strong>UniXell Biotechnology<\/strong>, a clinical-stage cell therapy innovator, announced that China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> has granted <strong>Investigational New Drug (IND) approval<\/strong> to initiate clinical studies of <strong>UX-GIP001<\/strong>, the company\u2019s proprietary <strong>universal induced pluripotent stem cell (iPSC)-derived cell therapy<\/strong> for <strong>drug-resistant epilepsy<\/strong>. This marks a pivotal step toward validating a <strong>disease-modifying approach<\/strong> that addresses the root cause of epileptic seizures by restoring dysfunctional neural circuits.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th><strong>Item<\/strong><\/th><th><strong>Detail<\/strong><\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>IND clearance for Phase I\/II clinical trial<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>UX-GIP001 (allogeneic iPSC-derived inhibitory neural progenitor cells)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Drug-resistant focal epilepsy in adults<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>9 Apr 2026<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Patient enrollment initiation within Q3 2026; primary endpoint: safety and seizure frequency reduction at 6 months<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-therapy-profile-amp-mechanism-of-action\">Therapy Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform<\/strong>: Universal (off-the-shelf) iPSC-derived cell therapy with proprietary hypoimmunogenic engineering<\/li>\n\n\n\n<li><strong>Target<\/strong>: Dysfunction of <strong>GABAergic inhibitory interneurons<\/strong> in epileptic foci<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Differentiated inhibitory neural progenitor cells integrate into host circuitry, restore GABA-mediated inhibition, and rebalance excitatory-inhibitory tone<\/li>\n\n\n\n<li><strong>Innovation<\/strong>: First <strong>disease-modifying<\/strong> cell therapy for epilepsy; contrasts with conventional anti-seizure medications that merely suppress symptoms<\/li>\n\n\n\n<li><strong>Manufacturing<\/strong>: Closed, automated bioreactor process enabling scalable, consistent production under GMP<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-preclinical-evidence\">Preclinical Evidence<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th><strong>Model<\/strong><\/th><th><strong>Endpoint<\/strong><\/th><th><strong>UX-GIP001 Result<\/strong><\/th><th><strong>Control<\/strong><\/th><th><strong>Significance<\/strong><\/th><\/tr><\/thead><tbody><tr><td>Chronic Epileptic Rat<\/td><td>Seizure Frequency (weekly)<\/td><td>\u2193 78%<\/td><td>No change<\/td><td><em>p<\/em> &lt; 0.001<\/td><\/tr><tr><td>Human Neural Organoid<\/td><td>GABA Synapse Density<\/td><td>\u2191 3.2-fold<\/td><td>Baseline<\/td><td><em>p<\/em> = 0.004<\/td><\/tr><tr><td>Immunodeficient Mouse<\/td><td>Cell Survival (90 days)<\/td><td>&gt;85% engraftment<\/td><td>N\/A<\/td><td>Stable functional integration<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Data demonstrated sustained seizure suppression without immunosuppression and no tumorigenicity across 12-month observation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Need<\/strong>: ~30% of epilepsy patients are drug-resistant; current options limited to invasive surgery or palliative care<\/li>\n\n\n\n<li><strong>Competitive Edge<\/strong>: Only iPSC-derived therapy targeting neural circuit restoration; potential to redefine standard of care<\/li>\n\n\n\n<li><strong>Commercial Strategy<\/strong>: Orphan drug designation pursuit in US\/EU; partnership talks with global neurology-focused pharma underway<\/li>\n\n\n\n<li><strong>Valuation Impact<\/strong>: Positions UniXell as a leader in CNS regenerative medicine; estimated market opportunity exceeds $2.5B globally by 2030<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory pathways, and commercial potential. Actual results may differ due to clinical trial outcomes, manufacturing challenges, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>UniXell Biotechnology, a clinical-stage cell therapy innovator, announced that China\u2019s National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":62719,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[77,62,833],"class_list":["post-62718","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cell-therapy","tag-clinical-trial-approval-initiation","tag-unixell-biotechnology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>UniXell Biotechnology Secures NMPA IND Approval for UX-GIP001, World\u2019s First iPSC-Derived Cell Therapy for Drug-Resistant Epilepsy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"UniXell Biotechnology, a clinical-stage cell therapy innovator, announced that China\u2019s National Medical Products Administration (NMPA) has granted Investigational New Drug (IND) approval to initiate clinical studies of UX-GIP001, the company\u2019s proprietary universal induced pluripotent stem cell (iPSC)-derived cell therapy for drug-resistant epilepsy. This marks a pivotal step toward validating a disease-modifying approach that addresses the root cause of epileptic seizures by restoring dysfunctional neural circuits.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62718\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"UniXell Biotechnology Secures NMPA IND Approval for UX-GIP001, World\u2019s First iPSC-Derived Cell Therapy for Drug-Resistant Epilepsy\" \/>\n<meta property=\"og:description\" content=\"UniXell Biotechnology, a clinical-stage cell therapy innovator, announced that China\u2019s National Medical Products Administration (NMPA) has granted Investigational New Drug (IND) approval to initiate clinical studies of UX-GIP001, the company\u2019s proprietary universal induced pluripotent stem cell (iPSC)-derived cell therapy for drug-resistant epilepsy. This marks a pivotal step toward validating a disease-modifying approach that addresses the root cause of epileptic seizures by restoring dysfunctional neural circuits.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62718\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-09T12:05:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-09T12:06:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0902.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62718#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62718\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"UniXell Biotechnology Secures NMPA IND Approval for UX-GIP001, World\u2019s First iPSC-Derived Cell Therapy for Drug-Resistant Epilepsy\",\"datePublished\":\"2026-04-09T12:05:59+00:00\",\"dateModified\":\"2026-04-09T12:06:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62718\"},\"wordCount\":359,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62718#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0902.webp\",\"keywords\":[\"Cell-therapy\",\"Clinical trial approval \\\/ initiation\",\"Unixell Biotechnology\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62718#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62718\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62718\",\"name\":\"UniXell Biotechnology Secures NMPA IND Approval for UX-GIP001, World\u2019s First iPSC-Derived Cell Therapy for Drug-Resistant Epilepsy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62718#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62718#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0902.webp\",\"datePublished\":\"2026-04-09T12:05:59+00:00\",\"dateModified\":\"2026-04-09T12:06:01+00:00\",\"description\":\"UniXell Biotechnology, a clinical-stage cell therapy innovator, announced that China\u2019s National Medical Products Administration (NMPA) has granted Investigational New Drug (IND) approval to initiate clinical studies of UX-GIP001, the company\u2019s proprietary universal induced pluripotent stem cell (iPSC)-derived cell therapy for drug-resistant epilepsy. This marks a pivotal step toward validating a disease-modifying approach that addresses the root cause of epileptic seizures by restoring dysfunctional neural circuits.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62718#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62718\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62718#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0902.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0902.webp\",\"width\":1080,\"height\":608,\"caption\":\"UniXell Biotechnology Secures NMPA IND Approval for UX-GIP001, World\u2019s First iPSC-Derived Cell Therapy for Drug-Resistant Epilepsy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62718#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"UniXell Biotechnology Secures NMPA IND Approval for UX-GIP001, World\u2019s First iPSC-Derived Cell Therapy for Drug-Resistant Epilepsy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"UniXell Biotechnology Secures NMPA IND Approval for UX-GIP001, World\u2019s First iPSC-Derived Cell Therapy for Drug-Resistant Epilepsy - Insight, China&#039;s Pharmaceutical Industry","description":"UniXell Biotechnology, a clinical-stage cell therapy innovator, announced that China\u2019s National Medical Products Administration (NMPA) has granted Investigational New Drug (IND) approval to initiate clinical studies of UX-GIP001, the company\u2019s proprietary universal induced pluripotent stem cell (iPSC)-derived cell therapy for drug-resistant epilepsy. This marks a pivotal step toward validating a disease-modifying approach that addresses the root cause of epileptic seizures by restoring dysfunctional neural circuits.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62718","og_locale":"en_US","og_type":"article","og_title":"UniXell Biotechnology Secures NMPA IND Approval for UX-GIP001, World\u2019s First iPSC-Derived Cell Therapy for Drug-Resistant Epilepsy","og_description":"UniXell Biotechnology, a clinical-stage cell therapy innovator, announced that China\u2019s National Medical Products Administration (NMPA) has granted Investigational New Drug (IND) approval to initiate clinical studies of UX-GIP001, the company\u2019s proprietary universal induced pluripotent stem cell (iPSC)-derived cell therapy for drug-resistant epilepsy. This marks a pivotal step toward validating a disease-modifying approach that addresses the root cause of epileptic seizures by restoring dysfunctional neural circuits.","og_url":"https:\/\/flcube.com\/?p=62718","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-09T12:05:59+00:00","article_modified_time":"2026-04-09T12:06:01+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0902.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62718#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62718"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"UniXell Biotechnology Secures NMPA IND Approval for UX-GIP001, World\u2019s First iPSC-Derived Cell Therapy for Drug-Resistant Epilepsy","datePublished":"2026-04-09T12:05:59+00:00","dateModified":"2026-04-09T12:06:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62718"},"wordCount":359,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=62718#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0902.webp","keywords":["Cell-therapy","Clinical trial approval \/ initiation","Unixell Biotechnology"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62718#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62718","url":"https:\/\/flcube.com\/?p=62718","name":"UniXell Biotechnology Secures NMPA IND Approval for UX-GIP001, World\u2019s First iPSC-Derived Cell Therapy for Drug-Resistant Epilepsy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=62718#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=62718#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0902.webp","datePublished":"2026-04-09T12:05:59+00:00","dateModified":"2026-04-09T12:06:01+00:00","description":"UniXell Biotechnology, a clinical-stage cell therapy innovator, announced that China\u2019s National Medical Products Administration (NMPA) has granted Investigational New Drug (IND) approval to initiate clinical studies of UX-GIP001, the company\u2019s proprietary universal induced pluripotent stem cell (iPSC)-derived cell therapy for drug-resistant epilepsy. This marks a pivotal step toward validating a disease-modifying approach that addresses the root cause of epileptic seizures by restoring dysfunctional neural circuits.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62718#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62718"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=62718#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0902.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0902.webp","width":1080,"height":608,"caption":"UniXell Biotechnology Secures NMPA IND Approval for UX-GIP001, World\u2019s First iPSC-Derived Cell Therapy for Drug-Resistant Epilepsy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62718#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"UniXell Biotechnology Secures NMPA IND Approval for UX-GIP001, World\u2019s First iPSC-Derived Cell Therapy for Drug-Resistant Epilepsy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0902.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62718","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62718"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62718\/revisions"}],"predecessor-version":[{"id":62720,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62718\/revisions\/62720"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/62719"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62718"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62718"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62718"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}